Symrise stock edges lower as AmeriTerpenes divestment brings disposal loss

Symrise stock is trading slightly weaker on September 2, 2026, as the company sharpens its portfolio by selling its AmeriTerpenes terpene ingredients business to Mutares, a move that will trigger a mid-double-digit million-euro non-cash disposal loss in the 2026 accounts.

Symrise (ISIN DE000SYM9999) stock is trading modestly lower on September 2, 2026, while the German fragrance and flavor specialist reshapes its portfolio by divesting its US-based AmeriTerpenes terpene ingredients business to private equity investor Mutares. According to market data, Symrise shares last changed hands at 91.82 euros on Xetra, down 0.65 percent from the previous close, with an intraday high of 93.32 euros and a low of 91.46 euros as of 11:35 on September 2, 2026.

Divestment of AmeriTerpenes hits 2026 earnings

The strategic catalyst for Symrise stock today is the announced sale of its terpene ingredients business AmeriTerpenes to Mutares, a transaction that continues the company’s portfolio management under its ONE Symrise strategy. As reported by a Webwire release dated September 2, 2026, Symrise has signed an agreement to divest AmeriTerpenes, positioning the business for long-term growth under Mutares’ ownership while sharpening Symrise’s focus on core activities.

The financial impact is clearly quantified: Symrise expects the AmeriTerpenes divestment to result in a non-cash disposal loss in the mid-double-digit million-euro range, which will be recognized in its annual financial statements for 2026. This means that, for 2026 reported earnings, the transaction will subtract somewhere between about 50 million and 90 million euros from profit, even though the loss is non-cash and relates primarily to accounting treatment rather than ongoing operations, as highlighted in coverage by Chemanalyst and SpecialChem.

Investor angle: earnings optics versus strategy

For investors in Symrise stock, the AmeriTerpenes sale adds an earnings headwind in 2026 but also underlines management’s willingness to prune non-core activities. The mid-double-digit million-euro disposal loss will weigh on reported net income for fiscal year 2026 compared with 2025 figures, where such a disposal effect did not appear. While exact prior-year profit numbers are not yet part of today’s disclosures, the quantified loss range gives the market a concrete reference point for how much lower 2026 earnings could be solely due to this transaction.

At the same time, Symrise signals that the divested AmeriTerpenes unit will continue under Mutares, suggesting a focus by Symrise on higher-margin and more strategically central segments in its flavor, fragrance, and care portfolio. The company has in recent years built out its health and beauty offering, including establishing a Care and Wellness Division after acquiring Swedish probiotics player Probi in 2025, as discussed in industry interviews reported by NIE Magazine. Against that backdrop, the AmeriTerpenes divestiture can be seen as part of a broader shift toward segments where Symrise sees more durable growth.

From a valuation standpoint, the current Xetra price of 91.82 euros leaves Symrise shares trading a few euros below the one-year target estimate of 96.69 euros cited in a same-day overview from a major financial portal, implying upside of roughly 5 percent if that consensus target is reached. That gap illustrates how the market balances the negative optics of a disposal loss against the potential longer-term benefits of a streamlined, higher-focus portfolio.

Care and Wellness products as growth driver

One concrete example of Symrise’s strategic direction after the AmeriTerpenes divestment is its Care and Wellness offering, which integrates ingredients for health-focused personal care and nutrition. Following the acquisition of probiotics specialist Probi in 2025, Symrise created a Care and Wellness Division that organizes and delivers a broad portfolio of health and beauty ingredients under a more unified structure, as highlighted in interviews with division managers. This shift indicates that Symrise is allocating capital and management attention to platforms that combine fragrance, flavor, and functional ingredients for consumer wellness applications.

In practical terms, that means Symrise is supplying ingredients for products ranging from skin-care formulations to functional foods and supplements, where demand trends are supported by consumers’ interest in preventive health and natural formulations. For shareholders, the hope is that such segments can grow faster than more commoditized ingredient lines, helping to offset one-off effects such as the 2026 disposal loss from AmeriTerpenes and supporting earnings beyond the current fiscal year.

Symrise stock on Xetra: current price picture

On the market side, Symrise stock is quoted on Xetra under the ticker SY1, giving it direct visibility for German and international investors who trade through Frankfurt’s electronic platform. As of 11:35 on September 2, 2026, the Xetra price of 91.82 euros places the shares closer to their intraday low of 91.46 euros than to the intraday high of 93.32 euros, reflecting the slight 0.65 percent decline on the day reported by a live price overview at Investing.com. The same data snapshot shows trading volume of 248,030 shares for the session, which provides liquidity for investors who want to adjust positions around the AmeriTerpenes divestment news.

Symrise stock fact box

• Company: Symrise AG
• ISIN: DE000SYM9999
• WKN: SYM999
• Ticker: SY1
• Trading venue: Xetra
• Price (as of September 2, 2026, 11:35): 91.82 EUR
• Market capitalization: 12,000,000,000 EUR (as of September 2, 2026)
• Sector / Industry: Specialty chemicals, flavors and fragrances
• Index membership: MDAX